Trop-2 as an Actionable Biomarker in Breast Cancer.
作者信息
Cursano Giulia, Frigo Emanuele, Sajjadi Elham, Ivanova Mariia, Venetis Konstantinos, Guerini-Rocco Elena, Criscitiello Carmen, Curigliano Giuseppe, Fusco Nicola
机构信息
Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
School of Pathology, University of Milan, Milan, Italy.
出版信息
Curr Genomics. 2023 Nov 22;24(3):129-131. doi: 10.2174/1389202924666230726112233.
Abstract
摘要
相似文献
1
Trop-2 as an Actionable Biomarker in Breast Cancer.Trop-2作为乳腺癌中一种可用于指导治疗的生物标志物。
Curr Genomics. 2023 Nov 22;24(3):129-131. doi: 10.2174/1389202924666230726112233.
2
An electrochemical biosensor to assay Trop-2 of breast cancer cells fabricated by methylene blue-assisted assembly of DNA nanoparticles.一种电化学生物传感器，通过亚甲蓝辅助 DNA 纳米颗粒组装来检测乳腺癌细胞中的 Trop-2。
Biosens Bioelectron. 2024 Feb 15;246:115907. doi: 10.1016/j.bios.2023.115907. Epub 2023 Dec 5.
3
Trop-2 as a Therapeutic Target in Breast Cancer.Trop-2作为乳腺癌的治疗靶点。
Cancers (Basel). 2022 Nov 30;14(23):5936. doi: 10.3390/cancers14235936.
4
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.曲妥珠单抗联合紫杉类和铂类新辅助化疗治疗 HER2 阳性早期乳腺癌患者中，滋养层细胞表面抗原-2（Trop-2）表达与病理完全缓解的相关性。
Breast Cancer Res Treat. 2024 Jun;205(3):589-598. doi: 10.1007/s10549-024-07292-z. Epub 2024 Mar 8.
5
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.在转移性三阴性乳腺癌患者中 sacituzumab govitecan 与化疗对比的 III 期 ASCENT 研究中的生物标志物分析。
Ann Oncol. 2021 Sep;32(9):1148-1156. doi: 10.1016/j.annonc.2021.06.002. Epub 2021 Jun 8.
6
Trop-2 is a determinant of breast cancer survival.Trop-2是乳腺癌生存的一个决定因素。
PLoS One. 2014 May 13;9(5):e96993. doi: 10.1371/journal.pone.0096993. eCollection 2014.
7
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.靶向 TROP-2 的抗体药物偶联物：转移性乳腺癌的临床开发。
Breast. 2022 Dec;66:169-177. doi: 10.1016/j.breast.2022.10.007. Epub 2022 Oct 18.
8
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.针对表达Trop-2的三阴性乳腺癌中戈沙妥珠单抗疗效的预测生物标志物。
Oncotarget. 2020 Oct 27;11(43):3849-3862. doi: 10.18632/oncotarget.27766.
9
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.临床用药及获得性他莫昔芬耐药对乳腺癌细胞中 Trop-2 表达的改变。
Breast Cancer. 2022 Nov;29(6):1076-1087. doi: 10.1007/s12282-022-01389-3. Epub 2022 Jul 27.
10
Immunity to Trop-1, a newly identified breast cancer antigen, inhibits the growth of breast cancer in mice.Trop-1 是一种新鉴定的乳腺癌抗原，对其产生免疫可抑制小鼠乳腺癌的生长。
Vaccine. 2010 Nov 16;28(49):7757-63. doi: 10.1016/j.vaccine.2010.09.057. Epub 2010 Sep 29.
本文引用的文献
1
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.在晚期或转移性 HR+/HER2-和三阴性乳腺癌中应用德曲妥珠单抗偶联物：TROPION-PanTumor01 研究的 I 期结果。
J Clin Oncol. 2024 Jul 1;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 23.
2
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.响应导向的新辅助 sacituzumab govitecan 治疗局部三阴性乳腺癌：NeoSTAR 试验结果。
Ann Oncol. 2024 Mar;35(3):293-301. doi: 10.1016/j.annonc.2023.11.018. Epub 2023 Dec 12.
3
Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.癌症中Trop-2概述：从临床前研究到临床环境中的未来方向
Cancers (Basel). 2023 Mar 13;15(6):1744. doi: 10.3390/cancers15061744.
4
Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer.三阴性乳腺癌中 TROP-2 表达与临床病理特征和预后的相关性。
Sci Rep. 2022 Dec 28;12(1):22498. doi: 10.1038/s41598-022-27093-y.
5
Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.三阴性乳腺癌中的滋养细胞表面抗原 2（TROP2）表达。
BMC Cancer. 2022 Sep 24;22(1):1014. doi: 10.1186/s12885-022-10076-7.
6
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.戈沙妥珠单抗作为转移性三阴性乳腺癌二线治疗的3期ASCENT研究亚组分析
NPJ Breast Cancer. 2022 Jun 9;8(1):72. doi: 10.1038/s41523-022-00439-5.
7
TROP2: a potential marker in diagnosis of thyroid neoplasms.TROP2：一种甲状腺肿瘤诊断中的潜在标志物。
Ir J Med Sci. 2023 Feb;192(1):99-103. doi: 10.1007/s11845-022-02976-1. Epub 2022 Mar 30.
8
Oncogene-mediated metabolic gene signature predicts breast cancer outcome.癌基因介导的代谢基因特征可预测乳腺癌预后。
NPJ Breast Cancer. 2021 Oct 28;7(1):141. doi: 10.1038/s41523-021-00341-6.
9
Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.Trop-2 蛋白作为治疗靶点：基于 Trop-2 的抗体药物偶联物及其预测性生物标志物的综述。
Bosn J Basic Med Sci. 2022 Feb 1;22(1):14-21. doi: 10.17305/bjbms.2021.6100.
10
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.在转移性三阴性乳腺癌患者中 sacituzumab govitecan 与化疗对比的 III 期 ASCENT 研究中的生物标志物分析。
Ann Oncol. 2021 Sep;32(9):1148-1156. doi: 10.1016/j.annonc.2021.06.002. Epub 2021 Jun 8.
Zotero 插件